Recently, a discovery by McColl used wildtype RB1 mutation status as a surrogate marker of YAP1 expression and revealed that wildtype RB1 was associated with significantly shorter OS and PFS compared to patients with mutant RB1, in which with an obvious decreased chemo-refractory SCLC tumors (10). This evidence concerns the gene YAP1 and small cell lung carcinoma.